For research use only, not for therapeutic use.
CCT241736（Cat No.:I019786）is a potent and selective inhibitor of the mitogen-activated protein kinase kinase (MAPK) enzyme dual-specificity phosphatase 1 (DUSP1). By inhibiting DUSP1, CCT241736 disrupts the MAPK signaling pathway, which is crucial for cell proliferation, differentiation, and survival. This compound is particularly valuable in cancer research, as the MAPK pathway is often dysregulated in various cancers. CCT241736 shows potential for enhancing the effectiveness of existing therapies by targeting drug-resistant cancer cells, making it a promising candidate for the development of novel anti-cancer strategies.
| Catalog Number | I019786 |
| CAS Number | 1402709-93-6 |
| Molecular Formula | C₂₂H₂₃Cl₂N₇ |
| Purity | ≥95% |
| Storage | Store at -20°C |
| IUPAC Name | 6-chloro-7-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]-2-(1,3-dimethylpyrazol-4-yl)-1H-imidazo[4,5-b]pyridine |
| InChI | InChI=1S/C22H23Cl2N7/c1-14-17(13-29(2)28-14)21-26-19-20(18(24)11-25-22(19)27-21)31-9-7-30(8-10-31)12-15-3-5-16(23)6-4-15/h3-6,11,13H,7-10,12H2,1-2H3,(H,25,26,27) |
| InChIKey | AKJBLKUZXRMECW-UHFFFAOYSA-N |
| SMILES | CC1=NN(C=C1C2=NC3=NC=C(C(=C3N2)N4CCN(CC4)CC5=CC=C(C=C5)Cl)Cl)C |
| Reference | [1]. Bavetsias V, et al. Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. J Med Chem. 2012 Oct 25;55(20):8721-34. |
